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[Abstract] The protocol outlined represents a cost-effective, rapid and reliable method for the 
generation of high-titre viral pseudotype particles with the wild-type SARS-CoV spike protein 
on a lentiviral vector core using the widely available transfection reagent PEI. This protocol is 
optimized for transfection in 6-well plates; however it can be readily scaled to different production 
volumes according to application. This protocol has multiple benefits including the use of readily 
available reagents, consistent, high pseudotype virus production Relative Luminescence Units 
(RLU) titres and rapid generation of novel coronavirus pseudotypes for research into strain 
variation, tropism and immunogenicity/sero-prevalence. 
Keywords: SARS coronavirus, Lentiviral pseudotype, Virus neutralization 
 
[Background] The production and use of pseudotyped viral particles (PV) is widely established 
for many viruses, and applications in the fields of serology, surveillance and vaccine 
development are manifold (Temperton et al., 2015; Carnell et al., 2015). PVs have proven to be 
powerful tools to study the effects of viral envelope glycoprotein mutations on serological outcomes, 
viral tropism and immunogenicity studies especially when combined with epitope information. PVs 
are chimeric viral constructs in which the outer (surface) glycoprotein(s) of one virus is combined 
with the replication-defective viral core of another virus. PV allow for accurate, sequence-directed, 
sensitive antibody neutralization assays and antiviral screening to be conducted within a low 
biosecurity facility and offer a safe and efficient alternative to wildtype virus use, making them 
exquisitely beneficial for many emerging RNA viruses of pandemic potential. Many of the 
published protocols require modification of the SARS spike glycoprotein and/or expensive 
transfection reagents (Temperton, 2009). The protocol presented here utilizes the full-length, non-
codon-optimized spike protein in conjunction with the low-cost transfection reagent PEI, making 
this protocol widely applicable to many stakeholder laboratories. Figure 1 shows a cartoon of the 
lentiviral SARS-CoV PV production process directed by plasmid co-transfection. 
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Figure 1. Cartoon representation of the production of SARS pseudotypes. HEK293T/17 
cells are transfected with three plasmids, bearing the relevant genes (Lentiviral vector, 
packaging construct and SARS-CoV spike expression plasmid) for the production of SARS-
CoV Spike bearing lentiviral pseudotypes. This figure is modified from Carnell et al. (2015). 
 
Materials and Reagents 
 




Cell-Culture Treated Multidishes (6-well) (Thermo Fisher Scientific, Thermo 
ScientificTM, catalog number: 140675) 
3. Microcentrifuge tube Safe-Lock write-on graduated with lid latch 1.5 ml 
4. Sterile syringes (10 ml), Generic 
5. Millex-HA 0.45 µm filters (Merck, catalog number: SLHAM33SS) 
6. 96-well white plate (Thermo Fisher Scientific, Thermo ScientificTM, catalog number: 
136101) 
7. HEK 293T/17 cells (ATCC, catalog number: CRL-11268) 
8. Huh7 cells (Cell Signaling Technology, catalog number: 300156) 
9. Plasmids 
a. Glycoprotein expression plasmid: pCAGGS-SARS-CoV spike 
b. Lentiviral vector expressing firefly luciferase: pCSFLW 
c. Second-generation lentiviral packaging construct plasmid: p8.91 (expresses gag, pol 
and rev) 
Note: Information on the plasmids above can be found in Temperton et al. (2005) and 
Carnell et al. (2015). Plasmids available from Viral Pseudotype Unit, University of Kent. 
n.temperton@kent.ac.uk 
10. Dulbeccos modified Eagle medium (DMEM) with GlutaMAX (Thermo Fisher Scientific, 
catalog number: 31966021) supplemented with 10% foetal bovine serum (FBS) (Pan-
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Biotech, catalog number: P40-37500) and 1% penicillin/streptomycin (P/S) (Pan Biotech, 
catalog number: P06-07100) 
11. Gibco Reduced Serum media Opti-MEM®
 
(Thermo Fisher Scientific, catalog number: 
31985047) 
12. Branched Polyethyleneimine (PEI) solution at concentration of 1 mg/ml (Sigma-Aldrich, 
catalog number: 408727).  
Note: PEI is dissolved in dH2O to a concentration of 1 mg/ml and the pH is adjusted to 7 
using diluted (1:3) concentrated HCl. 
13. Phosphate-buffered saline (PBS) 
14. Trypsin-EDTA (0.05%), phenol red (Thermo Fisher Scientific, GibcoTM, catalog number: 
25300054) 
15. Positive control antibody (monoclonal/polyclonal or post-infection serum) that can 
neutralize the SARS pseudotype 
16. Bright GloTM
 




1. Class II biosafety cabinet (Thermo Fisher Scientific, Thermo ScientificTM, model: MSC-
AdvantageTM) 
2. Water bath or incubator 
3. Pipettes (Gilson, model: PIPETMAN® Classic, P2, P20, P200 and P1000) 
4. Optional: BIO-RAD TC20TM
 
Automated Cell Counter (Bio-Rad Laboratories, catalog 
number: 1450102EDU) 
5. Plate centrifuge (ELMI, model: SkyLine CM-6MT) 
6. Glomax 96 luminometer (Promega, model: GloMax® 96) 




A. Transfection steps 
Note: All steps should be carried out in a class II biosafety cabinet to avoid contamination. 
Timeline: Transfection24 h. 
1. 293T/17 cells should be subcultured into 6-well plates at a ratio that will deliver 70-
90% confluence at the time of transfection. Typically seeding 4 x 105 cells per well will 
achieve this level of confluency. Example is shown in Figure 2. 
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Figure 2. Example of the confluency expected prior to transfection of HEK293T/17 
cells 
 
Timeline: Day of transfection. 
2. DMEM/10% FBS/1% P/S and Opti-MEM®
 
should be pre-warmed to 37 °C using a water 
bath or an incubator. 
3. Prepare two labelled sterile 1.5 ml microcentrifuge tubes (tube 1 and tube 2) for each well 
of a 6-well plate which will be used for transfections. 
4. Add the following plasmid constructs for transfection to tube 1: 
pCAGGS-SARS-CoV spike: 450 ng 
p8.91-lentiviral vector: 500 ng 
pCSFLW: 750 ng 
5. Add 100 µl Opti-MEM®
 
to the plasmid DNA mix (tube 1). 
6. Add 100 µl Opti-MEM®
 
and 17.5 µl of 1 mg/ml PEI to tube 2. 
7. Incubation step: Mix both tubes by gently flicking and incubate for 5 min at room 
temperature (RT). 
8. After incubation, pipette the Opti-MEM®/PEI solution from tube 2 into the Opti-
MEM®/DNA solution in tube 1. 
9. Incubation step: Incubate the tube at RT for 20 min whilst gently flicking the tube to mix 
every 3-4 min. 
10. Whilst the transfection mix is incubating, the culture media on the 293T/17 cells should 
be removed and 2 ml of fresh DMEM/10% FBS/1% P/S added per well. It is imperative at 
this point to add culture media slowly to one side of the well to avoid detaching the 
adherent cell monolayer. 
11. After 20 min incubation, pipette the DNA/Opti-MEM®/PEI solution onto the 293T/17 cells 
by adding dropwise throughout the total surface area of the well. Swirl the 6-well plate(s) 
gently to ensure an even dispersal of reagent mix. 
12. Incubation step: Incubate the plate at 37 °C, 5% CO2 overnight (o/n). In our hands 
incubation times of between 12-16 h result in equivalent final PV production RLU titres. 
Timeline: 12-16 h post transfection. 
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13. Post o/n incubation the culture media on the cells should be carefully removed and 2 ml 
fresh DMEM/10% FBS/1% P/S added. Again, add media slowly to one side of the well to 
avoid cell detachment. 
14. Incubate the 6-well plates at 37 °C 5% CO2 o/n for 32-36 h. 
Timeline: 44-52 h post transfection. 
15. Supernatant containing the viral pseudotype particles are harvested using a 2.5 ml sterile 
syringe and subsequently filtered into Falcon or microcentrifuge tubes via a syringe 
driven Millex HA-0.45 µm filter. 
16. Store all filtered supernatants at -80 °C until downstream use. It is recommended that 
supernatant is stored as aliquots to avoid multiple freeze thaw cycles that may impact 
viral RLU titres. 
Note: Supernatant may be stored at 4 °C for up to one week with no detectable loss of RLU 
titre. 
17. Optional step: Additional culture media may be added to cells to allow a second harvest 18-
24 h later by adding further DMEM/10% FBS/1% P/S. In this case, extreme care must be 
taken in initial PV collection (step A15) to avoid damage to the cell monolayer. We have 
observed that cells in poor health after first harvest result in significantly lower PV 
production RLU titres upon second harvest. 
Note: A control pseudotype virus can be created by following the steps outlined above but 
omitting the pCAGGS-SARS-CoV spike construct. This produces particles that do not 
express a viral surface glycoprotein (Delta Env control, Figure 3). 
 
B. Titration steps (Figure 3) 
Note: Titration consists of transduction of reporter (in this case firefly luciferase) into target cells 
mediated by the viral glycoprotein expressed on the viral pseudotype (SARS-CoV spike). 
Controls for titration are provided via the inclusion of cell only and Delta Env columns. Control 
for transduction can be provided via a PV bearing the Vesicular stomatitis virus G protein (VSV-
G) which utilizes a ubiquitous receptor which results in high RLU titres in all cell lines tested. 
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Figure 3. 96-well plate set-up for pseudotype titration. Serial dilution step showing 
addition of 100 µl of pseudotype virus supernatant to each well of row A and dilution of 50 
µl taken from this well to row B. This process is continued to end of plate (row H) at which 
point the final 50 µl is discarded. Delta Env control is indicated in red (column 11) and 
cell only control is indicated in green (column 12). One set of pipette tips can be used per 
dilution series (plate). 
 
1. In a 96-well white plate add 50 µl of DMEM/10% FBS/1% P/S to the entire column of cell 
only control (see Figure 3 column 12). 
2. Add 50 µl of DMEM/10% FBS/1% P/S from row B to H that are to contain PV or Delta-Env 
control virus. 
3. Add 100 µl of SARS pseudotype virus supernatant to each well of row A (excluding 
control columns) and add 100 µl of Delta-Env to column 11 (see Figure 3). 
4. Remove 50 µl from row A virus-containing wells and perform two-fold serial dilutions down 
all the wells beneath it.  
5. With each dilution step use a pipette to mix 8 times by pipetting up and down and taking 
care not to produce air bubbles. 
6. After completing serial dilution the final 50 µl from the final well of each column should 
be discarded. 
Note: At this point each well should contain 50 µl of mixed DMEM and PV supernatant. 
7. Prepare a plate of susceptible target cells (Huh-7 for SARS PV), preferentially subcultured 
1:4 48 h before: 
a. Remove culture media from plate. 
b. Wash the plate twice with 2 ml of PBS and discard. 
c. Add 2 ml of trypsin to the plate to detach cells. 
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d. After cells have detached add 6 ml of DMEM/10% FBS/1% P/S to the plate to 
quench trypsin activity, and resuspend cells gently. 
e. Count cells using TC20TM
 
Automated Cell Counter or haemocytometer and add 1 x 
104 cells in a total volume of 50 µl to each well. 
8. Centrifuge plate for 1 min at 800 x g (Rcf) if there are visible droplets on the sides of the 
wells. 
9. Incubate the plate for 48 h at 37 °C 5% CO2. 
10. Read plate using Bright GloTM
 
luciferase assay system on a Glomax 96 luminometer (or 
equivalent). 
 
C. Pseudotype based neutralisation assay (pMN) 
Note: pMN is the Inhibition of PV mediated transduction via an antibody (or inhibitor) directed 
against the SARS glycoprotein. 
1. In a 96-well white plate add 50 µl of DMEM/10% FBS/1% P/S to rows B to H, columns 1-
12. 
2. Add known amount of antibody (example 5 µl HN and R sera in Figure 4) into wells of row 
A, columns 2-10 in a total volume of 100 µl DMEM/10% FBS/1% P/S. Add known amount 
(e.g., 5 µl) of positive and negative antisera into wells A11 and A12 as controls. 
 
 
Figure 4. Anti-SARS antibodies (post-infection sera HN and R) neutralization of 
SARS viral pseudotype entry into Huh7 cells. Two repeats are plotted for each serum 
sample. 
 
3. Remove 50 µl from row A wells and perform two-fold serial dilutions down all the wells 
beneath it. 
4. With each dilution step use a pipette to mix 15 times by pipetting up and down and taking 
care not to produce air bubbles. 
5. After completing serial dilution the final 50 µl from the final well of each column should 
be discarded. 
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Note: At this point each well should contain 50 µl of mixed DMEM and serial dilutions of 
antibody/inhibitor. 
6. Centrifuge plate for 1 min at 800 x g (Rcf) to ensure no inhibitor or liquid is located on the 
walls of the well. 
7. Using data obtained from the titration, calculate the amount of DMEM required to dilute your 
SARS-PV to obtain 1 x 106 RLU in 50 µl, with a total volume of 5 ml. For example with an 
RLU/ml of 1 x 108, 1 ml of PV should be mixed with 4 ml of DMEM. 
8. Mix this diluted PV solution using the multichannel pipette, and aliquot 50 µl into each well on 
the plate, with the exception of wells A6-A12 (cell only control). A1-A6 will serve as virus 
only control. 
9. Centrifuge plate for 1 min at 800 x g (Rcf) to ensure no virus is left on the walls of the well. 
10. Incubate the plates for 1 h at 37 °C 5% CO2, allowing time for the antibody/inhibitor to bind 
the SARS glycoprotein. 
11. Prepare a plate of susceptible target cells (Huh-7 for SARS PV), preferentially subcultured 
1:4 48 h before: 
a. Remove culture media from plate. 
b. Wash the plate twice with 2 ml of PBS and discard. 
c. Add 2 ml of trypsin to the plate to detach cells. 
d. After cells have detached add 6 ml of DMEM/10% FBS/1% P/S to the plate to quench 
trypsin activity, and resuspend cells gently. 
e. Count cells using TC20TM
 
Automated Cell Counter or haemocytometer and add 1 x 
104 cells in a total volume of 50 µl to each well. 
12. Incubate the plate for 48 h at 37 °C 5% CO2. 
13. Read plate using Bright GloTM
 





1. RLU readings are multiplied to RLU/ml by the dilution factor of each well (20x, 40x, 80x, 
160x, 320x, 640x, 1,280x, 2,560x). The mean of all 8 RLU/ml values is used as the final 
value reported for that column in the titration step. A linear relationship should be observed 
between RLU values and PV dilution, with values decreasing by 50% after each 1:2 dilution. 
Care should be taken to check this linear relationship before multiplication, as this inherently 
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Table 1. Analysis of PV titration data. RLU values are multiplied to give an RLU/ml value 
(example highlighted in green) giving RLU/ml values for each of the dilution points. The 
mean/average is then calculated from all 8 dilution points. Care must be taken to observe a 
linear relationship between dilution factor (X factor) and RLU, or multiplication can lead to 
inflated RLU/ml values (example highlighted in yellow). 
X factor SARS-S VSV-G  Virus X 
20 5.58E+05 7.17E+08 3.05E+03 
40 2.90E+05 5.63E+08 1.10E+03 
80 1.43E+05 3.79E+08 6.29E+03 
160 6.17E+04 2.16E+08 8.80E+02 
320 3.10E+04 1.36E+08 5.43E+03 
640 2.41E+04 6.18E+07 3.39E+03 
1280 7.15E+03 3.06E+07 1.96E+03 
2560 3.62E+03 1.44E+07 3.33E+03 
    
RLU/ml 1.12E+07 1.43E+10 6.11E+04 
 1.16E+07 2.25E+10 4.40E+04 
 1.14E+07 3.03E+10 5.03E+05 
 9.87E+06 3.46E+10 1.41E+05 
 9.91E+06 4.35E+10 1.74E+06 
 1.54E+07 3.96E+10 2.17E+06 
 9.16E+06 3.92E+10 2.51E+06 
 9.26E+06 3.69E+10 8.54E+06 
    
Average 
RLU/ml 1.10E+07 3.26E+10 1.96E+06 
 
2. Protocol read-out and titration results (Figure 5). 
 
 
Figure 5. Results of pseudotype production RLU titres using optimized transfection 
protocol. SARS; PV with SARS-CoV Spike on surface, Cell; cell only control, Delta Env; 
PV with no surface glycoprotein, VSV-G; PV with VSV-G on surface. 
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3. The protocol outlined provides a rapid and consistent method for the generation of high-
titre viral pseudotype particles expressing the SARS-CoV spike protein suitable for further 
downstream R&D applications. Efficient knock-down (neutralization) of SARS-CoV 
pseudotype virus entry using two post-infection sera (HN and R) demonstrates potential 
utility for vaccine immunogenicity and mAb/antiviral screening. The use of readily available 
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